2|0|Public
30|$|JC is {{employed}} by Cambridge University Hospitals NHS Foundation Trust and obligated to spend 50 % {{of his time}} on GSK clinical trial research via a <b>secondment</b> <b>agreement,</b> representing a significant relationship; however, he receives no benefits or compensation from GSK. JC acknowledges funding support from the Cambridge NIHR Comprehensive Biomedical Research Centre.|$|E
40|$|Thanks to Dave Maré and Lynda Sanderson for helpful comments. This {{analysis}} forms {{part of the}} author’s <b>secondment</b> <b>agreement</b> with Statistics New Zealand. Disclaimer This {{research was}} undertaken while Richard Fabling was on secondment to Statistics New Zealand. Access to the data {{used in this study}} was provided by Statistics NZ in accordance with the security and confidentiality provisions of the Statistics Act 1975. Only people authorised by the Act are allowed to see data about a particular business or organisation. The results of this work have been confidentialised to protect individual businesses from identification. The opinions, findings, recommendations, and conclusions expressed in this report are those of the authors. Statistics New Zealand, the Reserve Bank of New Zealand, and Motu take no responsibility for any omissions or errors in the information contained here. The results are based in part on tax data supplied by Inland Revenue to Statistics New Zealand under the Tax Administration Act 1994. This tax data must be used only for statistical purposes, and no individual information is published or disclosed in any other form, or provided back to Inland Revenue for administrative or regulatory purposes. Any person who had access to the unit...|$|E

